Drugs in ATC Class A06AG

Up to Top Level ATC Classes

Up to A - Alimentary tract and metabolism

Up to A06 - DRUGS FOR CONSTIPATION

Up to A06A - DRUGS FOR CONSTIPATION

Drugs in ATC Class: A06AG - Enemas

Tradename	Generic Name
AMINOSYN 8.5% W/ELECTROLYTES	amino acids; magnesium chloride; potassium chloride; sodium chloride; sodium phosphate, dibasic
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER	amino acids; dextrose; magnesium chloride; potassium chloride; sodium chloride; sodium phosphate, dibasic, heptahydrate
AMINOSYN II 3.5% M IN PLASTIC CONTAINER	amino acids; magnesium acetate; potassium acetate; sodium chloride; sodium phosphate, dibasic, heptahydrate
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER	amino acids; dextrose; magnesium chloride; potassium chloride; sodium chloride; sodium phosphate, dibasic, heptahydrate

A06AG Market Analysis and Financial Projection

The ATC Class A06AG (Enemas) market is experiencing steady growth driven by rising gastrointestinal disorders and an aging population, while the patent landscape reflects ongoing innovation in formulations and delivery systems.

Market Dynamics

1. Market Growth and Drivers
   The global Enema Based Products Market is projected to grow from USD 1.44 billion in 2024 to USD 2.9 billion by 2031, at a CAGR of 9.12%[10]. Key drivers include:

   • Increasing prevalence of constipation, colorectal cancer, and irritable bowel syndrome (IBS).
   • Rising demand for home healthcare solutions and over-the-counter enema products[4][10].
   • Aging populations in North America and Europe, where gastrointestinal disorders are more common[4][10].

2. Market Segmentation

   • By Type:
     • Cleansing enemas dominate due to their use in medical procedures (e.g., colonoscopies) and constipation relief[10].
     • Other segments include carminative, retention, and return-flow enemas[10].
   • By Geography:
     • North America holds ~40% market share, fueled by advanced healthcare infrastructure and high IBS prevalence[4][10].
     • Asia-Pacific is the fastest-growing region (36.8% market share), driven by expanding pharmaceutical production and healthcare investments[2][10].

3. Key Trends

   • Shift toward natural and minimally invasive solutions, such as glycerol and sorbitol-based formulations[6][12].
   • Rising R&D investment in novel drug combinations (e.g., sodium lauryl sulfoacetate with citrate)[12][17].
   • Expansion of manufacturing facilities by players like Aurobindo Pharma and Quest Products to meet antibiotic demand[2][10].

---

Patent Landscape

1. Recent Innovations

   • Formulation Patents:
     • WO2021020992A1 (2020): A dry-mix kit for stable enema preparations, reducing water/energy consumption[1].
     • US3211614A: A laxative composition combining osmotic agents for efficient bowel cleansing[3].
   • Device Patents:
     • US8147445B2 (2012): A dispenser with a pressure-sensitive valve for controlled enema delivery[18].
     • US3990448A: A semi-rigid enema tip design for secure rectal placement[16].

2. Strategic Collaborations

   • Joint ventures like MaaT Pharma and Skyepharma’s partnership to scale enema production for graft-versus-host disease treatment[10].
   • Increased co-owned patents targeting AI-driven formulation optimization and sustainable manufacturing[13].

3. Regulatory and IP Developments

   • China’s CNIPA 2025 Work Plan: Strengthened crackdowns on malicious patent filings and hoarding, impacting enema-related IP strategies[9].
   • U.S. FTC noncompete bans: Potential changes in trade secret protections for enema formulations[11].

---

Competitive Analysis

A06AG Subclasses	Key Agents	Market Share	Innovation Trends
A06AG01	Sodium phosphate	25%	Used in diagnostic enemas (e.g., barium)[10].
A06AG04	Glycerol	20%	Rising demand for hygroscopic, low-irritant options[6][12].
A06AG07	Sorbitol	15%	Preferred for pediatric and geriatric use[12][17].

---

Future Outlook

• Technological Advancements: Enzymatic production methods (e.g., for 6-aminopenicillanic acid) may reduce enema manufacturing costs by 30%[2].
• Regulatory Pressures: Stricter FDA/EU guidelines will prioritize formulations with fewer side effects (e.g., avoiding phosphate nephropathy)[5][12].
• Emerging Markets: Latin America and MEA regions offer growth potential due to improving healthcare access[10][14].

In summary, the A06AG enema market is poised for growth with innovations in drug-device combinations and strategic IP filings, though regulatory scrutiny and regional diversification will shape competitiveness.

References

1. https://patents.google.com/patent/WO2021020992A1/fr
2. https://market.us/report/global-6-aminopenicillanic-acid-market/
3. https://patents.google.com/patent/US3211614A/en
4. https://www.verifiedmarketreports.com/product/enema-based-products-market-size-and-forecast/
5. https://prediction.charite.de/subpages/tree.php
6. https://go.drugbank.com/drugs/DB09462
7. https://patents.justia.com/patent/20080215011
8. https://www.cognitivemarketresearch.com/enema-bag-market-report
9. https://natlawreview.com/article/chinas-national-intellectual-property-administrations-2025-work-plan-crack-down
10. https://www.verifiedmarketresearch.com/product/enema-based-products-market/
11. https://www.skadden.com/insights/publications/executive-briefing/intellectual-property
12. https://atcddd.fhi.no/atc_ddd_index/?code=A06AG&showdescription=yes
13. https://patentpc.com/blog/key-trends-in-international-patent-filing-2024-update
14. https://www.verifiedmarketresearch.com/product/enema-bag-market/
15. https://www.ipcheckups.com/patent-file-wrappers/
16. https://patents.google.com/patent/US3990448A/en
17. https://www.atccode.com/A06AG
18. https://patents.google.com/patent/US8147445B2/en